
Dr. Van Cutsem Discusses Regorafenib for the Treatment of Patients With Chemorefractory mCRC
Published: | Updated:
Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).


